Check out FDA’s Office of Pharmaceutical Quality (OPQ) FY2023 report on the State of Pharmaceutical Quality to learn more about the select quality indicators and trends that provide insight into the quality of the U.S. drug supply. Learn more: https://lnkd.in/gbr4N-2X The report also highlights emerging approaches to surveil, characterize, and advance pharmaceutical quality. FDA uses the Report on the State of Pharmaceutical Quality, in part, to inform regulatory decision making and quality surveillance activities.
About us
The Food and Drug Administration is an agency within the Department of Health and Human Services. The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. FDA has responsibility for regulating the manufacturing, marketing, and distribution of tobacco products to protect the public health and to reduce tobacco use by minors. FDA is responsible for advancing the public health by helping to speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health. FDA also plays a significant role in the Nation's counterterrorism capability. FDA fulfills this responsibility by ensuring the security of the food supply and by fostering development of medical products to respond to deliberate and naturally emerging public health threats.
- Website
-
http://www.fda.gov/
External link for FDA
- Industry
- Government Administration
- Company size
- 10.001+ employees
- Headquarters
- Silver Spring, MD
- Type
- Government Agency
- Specialties
- Food, Drugs, Medical Devices, Vaccines Blood and Biologics, Animal and Veterinary, Cosmetics, Radiation-Emitting Products, Tobacco Products, Regulatory Research, and Toxicological Regulatory Research
Locations
-
Primary
10903 New Hampshire Ave
Silver Spring, MD 20993, US
Employees at FDA
Updates
-
FDA approves a treatment for primary biliary cholangitis (PBC) in adult patients, a rare autoimmune disease in the small bile ducts in the liver become injured and inflamed: https://lnkd.in/evmJW2Ds
-
📢 Register now for our free CE webinar on June 18 from 1-2 PM ET, to learn how to use the Orange Book to find therapeutic equivalence, marketing status, patents, & exclusivities information, including a discussion on commonly asked questions. Register➡️ https://lnkd.in/eeFnQuU9
-
FDA launched the Emerging Drug Safety Technology Program (EDSTP) to foster engagement and mutual learning between industry and FDA on the use of emerging technology tools, such as artificial intelligence (AI), to advance pharmacovigilance: https://lnkd.in/en_Ev2rE
-
Today, the U.S. Department of Justice (DOJ) and the U.S. Food and Drug Administration (FDA) announced the creation of a federal multi-agency task force to combat the illegal distribution and sale of e-cigarettes. https://lnkd.in/d86tqKCp “Enforcement against illegal e-cigarettes is a multi-pronged issue that necessitates a multi-pronged response,” said Dr. Brian King, the Director of FDA’s Center for Tobacco Products. “This ‘All Government’ approach – including the creation of this new Task Force – will bring the collective resources and experience of the federal government to bear on this pressing public health issue.” Along with the FDA and the Justice Department, the task force will bring together multiple law enforcement partners, including the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF); the U.S. Marshals Service (USMS); the U.S. Postal Inspection Service (USPIS); and the Federal Trade Commission (FTC) to coordinate and streamline efforts to bring all available criminal and civil tools to bear against the illegal distribution and sale of e-cigarettes responsible for nicotine addiction among American youth. Additional agencies may join the Task Force in the coming weeks and months.
-
FDA’s Complex Innovative Trial Design (CID) Paired Meeting Program is accepting meeting requests for this quarter until June 30, 2024: https://lnkd.in/gJRBrX72
-
Treatment of #OUD is most effective when medications are used. Learn how to integrate them into your primary care practice. Learn more at: https://lnkd.in/eaE8DRvf. #PrescribeWithConfidence #MOUDSavesLives #MedEd #recovery
-
Join FDA's Oncology Center of Excellence for the 9th Annual Clinical Outcome Assessment in Cancer Clinical Trials Workshop, June 25, 2024, 11 am to 2:30 pm ET. Each year, the COA-CCT workshop provides a forum for multidisciplinary discussions to advance the understanding of regulatory, health care policy, and scientific issues surrounding the use of patient-reported outcome (PRO) measures in cancer clinical trials. Agenda and session panelist biographies now posted. View event details and register now! https://lnkd.in/e5Zjjr8D #OCEOutcomes24
-
Happy #WorldFoodSafetyDay2024! 🎉 This year's theme from FAO and World Health Organization is “Food Safety: Prepare for the Unexpected.” Join the FDA on World Food Safety Day as we spread the word about ways to reduce the risks of foodborne illness, aka food poisoning. https://lnkd.in/ebP5CwD FDA is responsible for promoting and protecting the public's health by ensuring that the nation's food supply is safe, sanitary, wholesome, and honestly labeled. Remember, food safety is everyone’s business. #foodsafety #worldfoodsafetyday
-
📣Join FDA and Clinical Trials Transformation Initiative (CTTI) August 6, 2024 (10:00 AM - 5:30 PM EDT) for a free hybrid public workshop on artificial intelligence (AI) in drug and biological product development. AI holds great potential to transform how drugs are developed, manufactured, and utilized. As with any innovation, AI use in drug development creates new and unique challenges that require both careful management and a risk-based regulatory framework that is built on sound regulatory science approaches. This public workshop will explore guiding principles that are being applied by innovators and regulators to promote the responsible use of AI in the development of safe and effective drugs. Register today ➡️ https://lnkd.in/eP99VH_2